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Background: Lubiprostone is a synthetic bicyclic fatty acid derivative of prostaglandin E1 (PGE1) used for chronic
constipation. The best known action of lubiprostone is simulation of Cl- dependent fluid secretion. In a mouse
model of the genetic disease cystic fibrosis, we previously showed that in vivo administration of lubiprostone
resulted in greater mucus accumulation in the small intestine. The aim of this study was to directly test whether
lubiprostone stimulates intestinal mucin release.
Methods: Mucin release was measured by mounting segments (4-5 cm) of mouse proximal-mid small intestine in
an organ bath, allowing access to the perfusate (luminal) and the bath (serosal) solutions. Nifedipine (10-6 M) and
indomethacin (10-5 M) were included in all solutions to inhibit smooth muscle activity and endogenous
prostaglandin production, respectively. The tissue was equilibrated under flow for 30 min, using the perfusate
collected during the final 10 min of the equilibration period to measure unstimulated release rate. Stimulus was
then added to either the perfusate or the bath and the perfusate was collected for another 30 min to measure the
stimulated mucin release rate. Mucin in perfusates was quantified by periodic acid-Schiff's base dot-blot assay, using
purified pig gastric mucin as a standard.
Results: When applied luminally at 1 μM lubiprostone was ineffective at stimulating mucin release. When added to
the serosal solution, 1 μM lubiprostone stimulated mucin release to ~300% of the unstimulated rate. As a positive
control, serosal 1 μM prostaglandin E2 increased mucin release to ~400% of the unstimulated rate.
Conclusions: These results support the idea that lubiprostone has prostaglandin-like actions on the intestine, which
includes stimulation of mucin release. Stimulation of mucin release by lubiprostone may be protective in
gastrointestinal conditions where loss of mucus is believed to contribute to pathogenesis. Thus, in addition to
chronic constipation, there is greater potential for the therapeutic applications of lubiprostone.
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Lubiprostone is a synthetic bicyclic fatty acid derivative of
prostaglandin E1 used for chronic constipation. The best
known action of lubiprostone is simulation of Cl-
dependent fluid secretion. The originally proposed mecha-
nism of lubiprostone is activation of the CLC2 chloride
channel but this is controversial [1]. Recent work suggests
that lubiprostone may act in a prostaglandin-like manner
to stimulate cystic fibrosis transmembrane conductance
regulator (CFTR) dependent Cl- and fluid secretion [2].Correspondence: rdelisle@kumc.edu
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reproduction in any medium, provided the orIn the genetic disease cystic fibrosis (CF) there is
impaired Cl- and fluid secretion by affected epithelia con-
tributing to the pathophysiology in this disease. Because
lubiprostone can stimulate Cl- secretion, we had pre-
viously investigated its use as a therapy for CF by testing
its effects in a mouse model of CF, a Cftr knockout [3].
Treatment of CF mice with lubiprostone did ameliorate
some of the CF related alterations. Lubiprostone treatment
of CF mice accelerated gastric emptying, decreased small
intestinal bacterial overgrowth, and reduced inflammation.
These effects are independent of lubiprostone’s ability to
stimulate Cl- secretion because intestinal tissue from CF
mice does not secrete Cl- in response to lubiprostone [2].
Unexpectedly, in vivo administration of lubiprostone toThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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small intestine [3], mucus accumulation being one of the
major phenotypes of CF. This effect on mucus accumula-
tion is consistent with lubiprostone acting through a pros-
taglandin receptor, as prostaglandin E2 (PGE2) is a known
potent stimulus for intestinal mucin release. Therefore, in
this project we investigated the ability of lubiprostone to
stimulate mouse intestinal mucin secretion, using an
ex vivo organ bath approach.
Methods
Measurement of intestinal mucin release using an ex vivo
system
Mucin released was measured similar to that described
in [4]. Male C57BL/6 J mice (Jackson Labs, Bar Harbor,
ME) were used at 10–12 weeks of age. All animal work
was approved by the Institutional Animal Care and Use
Committee of the University of Kansas Medical Center.
Mice were killed by CO2 asphyxiation and cervical dis-
location. The small intestine was removed into ice cold
phosphate buffered saline (PBS) containing nifedipine
(10-6 M) and indomethacin (10-5 M) to inhibit smooth
muscle activity and endogenous prostaglandin produc-
tion, respectively. After discarding the proximal most
4 cm of the small intestine, the next two adjacent seg-
ments of 4–5 cm of intestine (jejunum) were dissected
from each mouse. The number of segments reported as
(n) in the figure legends indicates the number of mice
used. These segments were mounted by securing with
thread at either end to fire-polished 1.2 mm diameter
glass capillaries (see Figure 1). A stainless steel tissue
holder (Biopac, Goleta, CA; catalog RXHOLDER-S) was
modified to accept one of the glass capillaries by attach-
ing a pair of plastic connectors (Cole-Parmer, Chicago,
IL; kit #6365-90; 1.6 mm elbows) to one another by
short pieces of tubing and epoxying them to the rod to
make a U-shaped connector at the bottom (Figure 1).
The other end of the U-shaped connector was attached
to sylastic tubing through a peristaltic pump (Fisher Sci-
entific, catalog 13-876-1) set to achieve a flow rate of
~0.2 mL min-1. The outflow tubing, attached to the
upper glass capillary, was positioned about 1 cm above
the upper level of the tissue to maintain a slight positive
pressure in the segment to keep the lumen open. The
lumen perfusate solution was PBS without glucose,
warmed to 37°C. The mounted tissue was placed verti-
cally in an organ bath (20 mL; Biopac). The bath was
filled with bicarbonate buffered Ringer’s solution con-
taining 10 mM glucose, continuously gassed with 95%
O2/5% CO2, and thermostated to 37°C. Nifedipine
(10-6) and indomethacin (10-5) were included in all
solutions. The tissue was equilibrated under flow
(~0.2 mL min-1) for 30 min. The perfusate collected
during the final 10 min of the equilibration period wasused to measure the unstimulated release rate. Stimulus
was then added to either the perfusate solution or the
bath solution, and the perfusate outflow was collected
for another 30 min. The perfusate outflow during this
latter period was used to measure the stimulated mucin
release rate.
Quantification of released mucins
Mucin in perfusates was quantified by periodic acid-
Schiff's base dot-blot assay, using a kit (Sigma; catalog
395B). Pig gastric mucin (Sigma, St. Louis, MO; catalog
M1778) was used as a standard, prepared by suspension
at 10 mg mL-1 in PBS using a probe-type sonicator. Ser-
ial 2-fold dilutions were prepared and in each assay
125 μg through 0.122 μg of mucin plus a blank were ap-
plied by vacuum filtration to nitrocellulose membrane in
a dot-blot apparatus (Bio-Rad, Hercules, CA). A stand-
ard series of gastric mucins was included on every dot-
blot. Perfusate outflow samples (50 μL) were applied in
duplicate to the membrane as well. The membrane was
removed from the apparatus and sequentially incubated
in 3% acetic acid for 10 min, 6X diluted periodic acid for
15 min, 3% acetic acid washing for 10 min, 6X diluted
Schiff ’s Reagent for 10 min, 5 mg mL-1 sodium metabi-
sulfite in water for 10 min, rinsing in water for 10 min,
followed by air drying. The dried blots were scanned
with a flatbed scanner (Hewlett Packard, Palo Alto, CA)
and relative intensities measured using OptiQuant soft-
ware (Kodak, Rochester, NY). The standard curve data
were analyzed and sample unknowns determined using
SigmaPlot software (Jandel Scientific, San Jose, CA;
'Standard Curves' feature in the 'Pharmacology' menu,
with ‘Log X-scale’ and ‘Predict unknowns’). The PeakFit
program (Jandel Scientific) was used to determine area
under the curve (AUC) for 20–30 time points (unstimu-
lated), and the 30–60 min time points (stimulated)
which are presented as μg mucin min-1 g-1 tissue.
Statistical analysis
Data are presented as means ± standard errors. When
there are 2 groups of data, a t-test was used. When there
are more than 2 groups an ANOVA with post-hoc
Tukey’s test was used. P-values <0.05 are considered sta-
tistically significant.
Results and discussion
To measure mucin release from mouse small intestine, an
ex vivo perfusion system was established similar to that in
[4] using modifications as described in the Methods
(Figure 1). It is assumed that with an adequate flow rate
and the presence of bicarbonate ion in the perfusate and
bath solutions, that the exocytosed mucins will expand
and be mobile enough to be quantitatively included in the
perfusate [4]. Mucin in perfusate outflow was quantified
Figure 1 Custom tissue holder for organ bath perfusion
studies. A stainless steel tissue holder was modified to hold a
4–5 cm segment of small intestine. The tissue was attached to the
fire-polished glass capillaries with sutures at either end. The
assembly was then placed in the 37°C thermostated organ bath
which was filled with bicarbonate buffered Ringer’s solution and
continuously gassed with 95% O2/5% CO2. The tissue was perfused
with PBS using a peristaltic pump at a flow rate of ~0.2 mL min-1.
The outflow was collected at 5 min intervals for the 1st 30 min
(equilibration) followed by addition of stimulus and collection of
outflow at 3 min intervals (stimulated).
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pig gastric mucin as a standard (see Methods). An ex-
ample of the dot-blot of the dilution series of pig gastric
mucin standards used is shown in Figure 2A. The intensity
of a serial 2-fold dilution series of`mucin from 125 μg -
0.12 μg shows that mucin is detectable down to ~1 μg in a
50 μL aliquot of perfusate outflow (Figure 2A). When the
data are analyzed using standard curve analysis software
(SigmaPlot) the nonlinear regression indicates a very good
fit (R2 = 0.997) (Figure 2B).
As a positive control, the known mucin secretagogue
PGE2 [4] was used. Examples from three independent
intestinal preparations are shown in Figure 2C. There is
variable mucin release during the equilibration period
which becomes uniformly low during the final 10 min of
equilibration. Upon addition of PGE2, there is an in-
crease in mucin release whose timing is somewhat va-
riable preparation-to-preparation (Figure 2C). Therefore,
the area under the curve was calculated, divided by the
30 min stimulation period, and mucin release is
expressed as μg mucin min-1 g-1 tissue, as shown in
Figure 3.
There is disagreement in the literature as to the mem-
brane surface where lubiprostone acts. In some experi-
ments, it was reported that lubiprostone acted when
applied to the apical surface of epithelia [1,5] and in
others when it was applied basolaterally [6]. Therefore,
we tested application of lubiprostone to either surface.
When applied to the luminal surface by addition to the
perfusate solution, lubiprostone (1 μM) had no effect on
mucin release (Figure 3A). Similar to luminal lubipros-
tone, luminal application of PGE2 (1 μM) also had no ef-
fect on mucin release (data not shown).
We next tested the effect on mucin release of lubi-
prostone added to the serosal surface (to the bath). For
comparison, we used PGE2. As shown in Figure 3B, both
PGE2 (1 μM) and lubiprostone (1 μM) stimulated mucin
release. PGE2 increased the rate of mucin release to
~400% that of the unstimulated (equilibration) rate
(Figure 3B). Lubiprostone also stimulated mucin release
to over 300% that of the unstimulated rate (Figure 3B).
The difference in stimulation of mucin release between
PGE2 and lubiprostone was not statistically significant.
Figure 2 Standard curve of pig gastric mucin and examples of
PGE2-stimulated mucin release. (A) Example of the dilution series of
pig gastric mucin. Purified pig gastric mucin was prepared in PBS and
2-fold serial dilutions were made. Mucin was applied to nitrocellulose
membrane in a dot-blot apparatus followed by periodic acid Schiff’s
reaction. The dried blot was imaged on a flatbed scanner and
analyzed as described in the Methods. (B) Standard curve generated
using SigmaPlot software. (n = 13 series of standards; R2 = 0.997)
(C) Examples of mucin release before and after addition of PGE2 (1 μM
final) to the bath (serosal) solution. The 20–30 min data (Equil) were
used to measure the area under the curve for the unstimulated period,
and 30–60 min data (Stimulation) were used to measure the area
under the curve for the stimulated period (Figure 2).
Figure 3 Effect of lubiprostone on intestinal mucin release.
(A) Luminal Lubiprostone. Lubiprostone (1 μM final) was added to the
perfusate (luminal) solution after a 30 min equilibration period. The
areas under the curves for 20–30 min data (Equilibration) and 30–
60 min data (1 μM Lubiprostone) were measured and divided by the
time period to determine the rates of mucin release. (n = 2 intestinal
segments) (B) Serosal PGE2, Lubiprostone. Vehicle (Control), PGE2
(1 μM final), or lubiprostone (Lubi, 1 μM final) was added to the bath
(serosal) solution after a 30 min equilibration period. The areas under
the curves for 20–30 min data (Equilibration; n = 26 intestinal
segments) and 30–60 min data (Control unstimulated, n = 10; PGE2,
n = 9; lubiprostone, n = 7) were measured and divided by the time
period to determine the rates of mucin release. (*) p<0.05 vs Control.
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http://www.biomedcentral.com/1471-230X/12/156Because lubiprostone also stimulates bicarbonate-rich
fluid secretion in the small intestine [7], it is likely that this
effect of lubiprostone facilitates solubilization of exocy-
tosed goblet cell mucin and its expansion to mucus. It has
been shown that co-secretion of bicarbonate through a
CFTR-dependent pathway is crucial for correct expansion
of exocytosed mucins [4,8]. Since lubiprostone also acti-
vates CFTR-dependent bicarbonate secretion, mucin re-
lease and bicarbonate will be simultaneously stimulated by
lubiprostone.After this study was submitted, a report was published
investigating the effects of lubiprostone stimulation in
intestinal loop preparations of rat intestines and ex vivo
human colonic samples [9]. They showed that lubipros-
tone caused a coordinated redistribution of several apical
and basolateral ion transporters between cytoplasmic
vesicles and the plasma membrane that collectively
would support secretion at the same time as suppressing
absorption, in villi of the small intestine and in colonic
crypts. They also quantified mucin granule exocytosis by
morphometric histological analyses and showed that
lubiprostone caused depletion of goblet cells mucin
granules in both small and large intestine. Our results
that lubiprostone stimulates mucin release ex vivo from
the mouse small intestine are in agreement with the
results of this study.
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The results of this study support the idea that lubipros-
tone has prostaglandin-like actions on the intestine, which
includes stimulation of mucin release. It remains to be
determined which prostaglandin receptor(s) is/are acti-
vated by lubiprostone in the stimulation of mucin exocy-
tosis by small intestinal goblet cells. It is known that
mucin exocytosis and bicarbonate-rich fluid secretion are
tightly coupled in the intestine [10] and that fluid secre-
tion is impaired in EP3 PGE2 receptor knockout mice
[11]. However, in human duodenum, fluid secretion can
be stimulated by an EP4 selective agonist [12] and an EP4
antagonist blocks bicarbonate secretion in rat duodenum
[7], making the EP4 receptor a likely candidate for media-
ting lubiprostone's effects on mucin release. Regardless of
which prostaglandin receptor is involved, stimulation of
mucin release by lubiprostone may be protective in gastro-
intestinal conditions where loss of mucus is believed to
contribute to pathogenesis [13]. Thus, in addition to
chronic constipation, there is greater potential for the
therapeutic applications of lubiprostone.
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